research chemical comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
=== Joint involvement === Approximately 60% of MCTD patients develop visible arthritis, frequently with rheumatoid arthritis (RA) deformities such as boutonniere deformities and swan neck alterations. Other features include tiny marginal erosions and destructive arthritis, such as arthritis mutilans.
substituent An atom or a group of atoms which substitutes or replaces another atom or group of atoms within a larger molecule as the product of a chemical reaction, thereby becoming a moiety of the newly formed compound, generally without causing any significant change to other parts of the same molecule. For example, a hydroxyl group may be substituted for any of the hydrogen atoms in benzene to form phenol. See also side chain and functional group.
== Structure == The secondary structure consists of 13 beta-pleated sheets, 2 alpha-helices, 2 310-helices, and 8 loop regions. In terms of amino acid sequences, hK6 is most similar to myelencephalon-specific protease (MSP), which comes from the rat kvllikrein gene family. MSP and hK6 both target the peptide bond where arginine follows and they both automatically cleave themselves at their Arg positions. However, structurally, hK6 most resembles trypsin found in cows/oxen. Surrounding the active site, there are short loop regions that point away from the binding site. In the binding site, residues 189-195, 214-220, and 224-228 are found in addition to the Asp, His, and Ser residues.
Sources: en.wikipedia.org
Breastfeeding delays the return of menstruation, and in very specific circumstances, fertility, a phenomenon known as lactational amenorrhea. Long-term benefits for the mother include decreased risk of breast cancer, cardiovascular disease, diabetes, metabolic syndrome, and rheumatoid arthritis. Breastfeeding is less expensive than infant formula, but its impact on mothers' ability to earn an income is not usually factored into calculations comparing the two feeding methods. It is also common for women to experience symptoms such as: vaginal dryness, De Quervain syndrome, cramping, mastitis, moderate to severe nipple pain, and a general lack of bodily autonomy. These symptoms generally peak at the start of breastfeeding but disappear or become considerably more manageable after the first few weeks. Each feeding may last as long as 30–60 minutes, as milk supply develops and the infant learns the Suck-Swallow-Breathe pattern. However, as milk supply increases and the infant becomes more efficient at feeding, the duration of feeds may shorten to as little as 5-10 minutes per breast. While newborns and young babies feed 8-12 times per 24 hours, older infants may feed less often. When direct breastfeeding is not possible, expressing or pumping to empty the breasts can help mothers avoid plugged milk ducts and breast infection, maintain their milk supply, resolve engorgement, and provide milk to be fed to their infant at a later time. Medical conditions that do not allow breastfeeding are rare.
Shunting inhibition has no direct effect on the membrane potential of the cell; however, it reduces the effect of any coincident synaptic input by reducing the electrical resistance of the cell's membrane. Shunting inhibition can "override" the excitatory effect of depolarising GABA, resulting in overall inhibition even if the membrane potential becomes less negative. It was thought that a developmental switch in the molecular machinery controlling the concentration of chloride inside the cell changes the functional role of GABA between neonatal and adult stages. As the brain develops into adulthood, GABA's role changes from excitatory to inhibitory.
"In 1971 I stressed protein complementarity because I assumed that the only way to get enough protein ... was to create a protein as usable by the body as animal protein. In combating the myth that meat is the only way to get high-quality protein, I reinforced another myth. I gave the impression that in order to get enough protein without meat, considerable care was needed in choosing foods. Actually, it is much easier than I thought. "With three important exceptions, there is little danger of protein deficiency in a plant food diet. The exceptions are diets very heavily dependent on [1] fruit or on [2] some tubers, such as sweet potatoes or cassava, or on [3] junk food (refined flours, sugars, and fat). Fortunately, relatively few people in the world try to survive on diets in which these foods are virtually the sole source of calories. In all other diets, if people are getting enough calories, they are virtually certain of getting enough protein." The necessity of protein combining was not asserted. Rather, the increased biological value of meals where proteins are combined was noted. In a concession, Lappé removed from the second edition "charts that indicate exact proportions of complementary proteins". The American Dietetic Association reversed itself in its 1988 position paper on vegetarianism. Suzanne Havala, the primary author of the paper, recalls the research process:
==== Administering the department ==== The permanent under-secretary at the Environment Department, Sir John Garlick, described Heseltine's arrival as a change from "a very conservative Labour secretary of state, Peter Shore, to a very radical Conservative Secretary of State". On his first day Heseltine took him out to lunch at the Connaught and drew up a list of what he wanted to accomplish in office (the list appears in Heseltine's book Where There's A Will, and was returned to him at the end of his time at the Environment). Only a quarter of Heseltine's agenda consisted of manifesto commitments and other political goals; the rest of it consisted of administrative and organisational changes. Peter Hennessy observed that Heseltine was more interested in the nuts and bolts of Whitehall reform than any minister since David Lloyd George. Heseltine was quite ruthless about moving civil servants with whom he was dissatisfied, but nonetheless staff thought he had mellowed somewhat since the early 1970s, and was more relaxed and fun to work with. His permanent secretaries Sir John Garlick and Sir George Moseley thought highly of him. He preferred to reach decisions through informal discussion rather than wading through paperwork. He instituted Peter Walker's custom of morning "prayer" meetings (ministers and PPSs with no civil servants present), now common in Whitehall but an innovation at the time. The department had a budget of £14 billion a year and employed 52,000 people. The Conservatives were pledged to cut 100,000 off the 730,000 strong civil service.
Sources: en.wikipedia.org
=== Activism === Kardashian supports the recognition of the Armenian genocide and has visited Tsitsernakaberd, the memorial to the victims in Yerevan, Armenia. In April 2021, Kardashian praised President Joe Biden for officially recognizing the Armenian Genocide, thus becoming the first US president to do so. In October 2020, Kardashian spoke out in support of Republic of Artsakh and Armenians, condemning Azerbaijan's involvement in the 2020 Nagorno-Karabakh conflict. On October 10, 2020, she spoke on the ArmeniaFund fundraising telethon and urged viewers to donate money to help those impacted by the recent war.
=== ENSO Costero === Coined by the Peruvian Comité Multisectorial Encargado del Estudio Nacional del Fenómeno El Niño (ENFEN), ENSO Costero, or ENSO Oriental, is the name given to the phenomenon where the sea-surface temperature anomalies are mostly focused on the South American coastline, especially from Peru and Ecuador. Studies point many factors that can lead to its occurrence, sometimes accompanying, or being accompanied, by a larger EP ENSO occurrence, or even displaying opposite conditions from the observed ones in the other Niño regions when accompanied by Modoki variations. ENSO Costero events usually present more localized effects, with warm phases leading to increased rainfall over the coast of Ecuador, northern Peru and the Amazon rainforest, and increased temperatures over the northern Chilean coast, and cold phases leading to droughts on the Peruvian coast, and increased rainfall and decreased temperatures on its mountainous and jungle regions. Because they don't influence the global climate as much as the other types, these events present lesser and weaker correlations to other significant ENSO features, neither always being triggered by Kelvin waves, nor always being accompanied by proportional Southern Oscillation responses. According to the Coastal Niño Index (ICEN), strong El Niño Costero events include 1957, 1982–83, 1997–98 and 2015–16, and La Niña Costera ones include 1950, 1954–56, 1962, 1964, 1966, 1967–68, 1970–71, 1975–76 and 2013.
210Po is extremely toxic; it and other polonium isotopes are some of the most radiotoxic substances to humans. With one microgram of 210Po being more than enough to kill the average adult, it is 250,000 times more toxic than hydrogen cyanide by weight. This is a consequence of its ionizing alpha radiation, as alpha particles are especially damaging to organic tissues inside the body. However, 210Po does not pose a radiation hazard when kept outside the body. The alpha particles it produces cannot penetrate the outer layer of dead skin cells. The toxicity of 210Po stems entirely from its radioactivity. It is not chemically toxic in itself, but its solubility in aqueous solution as well as that of its salts poses a hazard because its spread throughout the body is facilitated in solution. Intake of 210Po occurs primarily through contaminated air, food, or water, as well as through open wounds. Once inside the body, 210Po concentrates in soft tissues (especially in the reticuloendothelial system) and the bloodstream. Its biological half-life is approximately 50 days. In the environment, 210Po can accumulate in seafood. It has been detected in various organisms in the Baltic Sea, where it can propagate in, and thus contaminate, the food chain. 210Po is also known to contaminate vegetation, primarily originating from the decay of atmospheric radon-222 and absorption from soil. In particular, 210Po attaches to, and concentrates in, tobacco leaves.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.